Skip to main content

Table 2 Comparison of investigative parameters among patients in each group

From: N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study

Investigations Group 1
PAH
Group 2
At Risk
Group 3
ILD
Group 4
Controls
Pvalue
TTE parameters      
   TRV (m/s) 3.8 ± 0.7 2.95 ± 0.3 2.54 ± 0.4 2.20 ± 0.2 < 0.0001
sPAP (mm Hg) 65.8 ± 27.3 43.8 ± 7.2 32.1 ± 5.3 26.3 ± 2.6 < 0.0001
RHC results      
   mPAP (mm Hg) 40.2 ± 12.5 N/A N/A N/A N/A
   mRAP (mm Hg) 10.1 ± 3.3 N/A N/A N/A N/A
PVR (Wood units) 6.2 ± 3.4 N/A N/A N/A N/A
PFT      
   FVC (% pred) 75.5 ± 23.4 100.6 ± 19.5 68.7 ± 13.2 102.8 ± 13.4 < 0.0001a
   DLCOcorr (% pred) 45.6 ± 11.7 61.0 ± 15.1 48.0 ± 12.7 86.8 ± 13.0 < 0.0001b
FVC/DLCOcorr 1.76 ± 0.38 1.73 ± 0.46 1.46 ± 0.31 1.20 ± 0.20 < 0.0001c
6MWD (m) 337 ± 100 N/A 458 ± 84 N/A N/A
Log NT-proBNP 6.72 ± 1.48 5.18 ± 1.11 4.72 ± 0.57 4.12 ± 0.63 < 0.0001
NT-proBNP (pg/ml) 1818 ± 2367 278 ± 243 133 ± 87 72 ± 38 < 0.0001d
  1. 6MWD, 6-minute walk distance; DLCO, diffusion capacity of lung for carbon monoxide (% predicted); FVC, forced vital capacity (% predicted); ILD, interstitial lung disease; mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure; NT-proBNP, N-terminal pro brain natriuretic peptide; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; sPAP, systolic pulmonary artery pressure; TRV, tricuspid regurgitant velocity. aLower FVC in PAH and ILD groups, versus "at risk" and controls
  2. bLower DLCO in PAH and ILD groups, versus "at risk" and controls. cHigher FVC/DLCO in PAH and "at risk" groups, versus ILD and controls. dHigher NT-ProBNP in PAH versus other groups, and "at risk" versus controls.